Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Streamlined Antibacterial Development Would Not Be Limited To First-In-Disease Products, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

A second product in a particular disease could still be considered as meeting an unmet need in certain circumstances, according to new draft guidance.

Advertisement

Related Content

GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D

Topics

Advertisement
UsernamePublicRestriction

Register

PS075994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel